Talk Bio

The FDA has launched the Adverse Event Monitoring System (AEMS), a unified platform consolidating disparate reporting systems for drugs, devices, food, cosmetics, vaccines, and more. 1 2 4 6 7 AEMS replaces outdated, fragmented systems to improve data access, aggregation, and research opportunities, with a single dashboard for adverse event reports. 2 4 The system aims to save $120 million by reducing administrative burdens and enhancing efficiency with AI tools and advanced analytics. 1 FDA Commissioner Marty Makary stated the previous systems wasted taxpayer dollars and created surveillance blind spots. 2 Full real-time reporting for all FDA-regulated products will be available by the end of May 2026, protecting patient privacy. 2 3 Electronic submission standards like E2B(R3) have implementation deadlines of April 1, 2026, for various reports. 4 5 Sources: 1. https://www.fiercepharma.com/pharma/fda-rolls-out-new-streamlined-adverse-event-monitoring-system 2. https://...